Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation.
- 1 December 1996
- Vol. 51 (12) , 1273-1274
- https://doi.org/10.1136/thx.51.12.1273
Abstract
Secretory leukoprotease inhibitor (SLPI) is a low molecular weight serine proteinase inhibitor, notably of neutrophil elastase (NE), which is synthesised and secreted by the pulmonary epithelium. SLPI plays an important role in limiting NE-induced pulmonary inflammation and, significantly, it also possesses anti-HIV activity. SLPI is a significant component of the anti-NE shield in the lung which has different reactivity from, and is therefore complementary to, the anti-NE action of alpha 1-proteinase inhibitor (alpha 1-PI). Inhaled recombinant SLPI (rSLPI) could prove beneficial in partnership with alpha 1-PI in the treatment of a number of inflammatory lung disorders including emphysema, chronic bronchitis, cystic fibrosis, and adult respiratory distress syndrome.Keywords
This publication has 11 references indexed in Scilit:
- Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.Journal of Clinical Investigation, 1995
- Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor.Thorax, 1995
- Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes.American Journal of Respiratory Cell and Molecular Biology, 1994
- Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitorBiochemical Journal, 1994
- Pharmacokinetics of Recombinant Secretory Leukoprotease Inhibitor Aerosolized to Normals and Individuals with Cystic FibrosisAmerican Review of Respiratory Disease, 1993
- Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 1993
- Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor.Journal of Clinical Investigation, 1992
- Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epitheliumJournal of Applied Physiology, 1990
- Effects of cigarette smoking and drugs on respiratory tract proteases and antiproteases.1987
- Kinetics of the inhibition of leukocyte elastase by the bronchial inhibitorBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982